Literature DB >> 11509610

Progressive depletion of peripheral B lymphocytes in 4-1BB (CD137) ligand/I-Ealpha)-transgenic mice.

G Zhu1, D B Flies, K Tamada, Y Sun, M Rodriguez, Y X Fu, L Chen.   

Abstract

Interaction of 4-1BB (CD137) and its ligand (4-1BBL) is thought to positively regulate cell-mediated and humoral immune responses. We have prepared transgenic mouse strains that express 4-1BBL cDNA under the control of MHC class II I-Ealpha promoter. The 4-1BBL-transgenic mice show progressive splenomegaly and selective depletion of B220(+) B cells accompanied with low levels of circulating IgG and defective humoral responses to Ag challenge. In addition, splenocytes from the transgenic mice fail to provide stimulation for allogeneic T cells in both lymphoproliferative and CTL responses in vitro, whereas their T cells remain functionally normal. Our results reveal unexpected functions of 4-1BBL in the regulation of humoral immune responses and Ag presentation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509610     DOI: 10.4049/jimmunol.167.5.2671

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Cross-linking of CD137 ligand modulates immune responses of thioglycollate-elicited mouse peritoneal macrophages.

Authors:  Jun-Sang Bae; Hyeong-Sup Kim; Jae Hong Park; Sang-Hyuk Park; Hyeon-Woo Lee
Journal:  Inflamm Res       Date:  2010-12-24       Impact factor: 4.575

2.  CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype.

Authors:  Yuwen Zhu; Gefeng Zhu; Liqun Luo; Andrew S Flies; Lieping Chen
Journal:  Blood       Date:  2007-01-23       Impact factor: 22.113

3.  Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Authors:  Liguo Niu; Simona Strahotin; Becker Hewes; Benyue Zhang; Yuanyuan Zhang; David Archer; Trent Spencer; Dirck Dillehay; Byoung Kwon; Lieping Chen; Anthony T Vella; Robert S Mittler
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

4.  Immunotherapy targeting 4-1BB and its ligand.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

5.  A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Authors:  Rich-Henry Schabowsky; Kutlu G Elpek; Shravan Madireddi; Rajesh K Sharma; Esma S Yolcu; Laura Bandura-Morgan; Robert Miller; Kathryn J MacLeod; Robert S Mittler; Haval Shirwan
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

6.  Leucocyte-associated immunoglobulin-like receptor-1 is an inhibitory regulator of contact hypersensitivity.

Authors:  Ryusuke Omiya; Fumihiko Tsushima; Hidehiko Narazaki; Yukimi Sakoda; Atsuo Kuramasu; Youn Kim; Haiying Xu; Hideto Tamura; Gefeng Zhu; Lieping Chen; Koji Tamada
Journal:  Immunology       Date:  2009-12       Impact factor: 7.397

Review 7.  Advances in targeting cell surface signalling molecules for immune modulation.

Authors:  Sheng Yao; Yuwen Zhu; Lieping Chen
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

8.  Hypercostimulation through 4-1BB distorts homeostasis of immune cells.

Authors:  Seung-Woo Lee; Shahram Salek-Ardakani; Robert S Mittler; Michael Croft
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

9.  Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells.

Authors:  Seung-Woo Lee; Yunji Park; Takanori So; Byoung S Kwon; Hilde Cheroutre; Robert S Mittler; Michael Croft
Journal:  Nat Immunol       Date:  2008-07-06       Impact factor: 25.606

10.  CD137-mediated immunotherapy for allergic asthma.

Authors:  Tobias Polte; Juergen Foell; Christoph Werner; Heinz-Gerd Hoymann; Armin Braun; Stefan Burdach; Robert S Mittler; Gesine Hansen
Journal:  J Clin Invest       Date:  2006-03-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.